Innocare Pharma
Innocare Pharma, a leading biopharmaceutical company headquartered in China (CN), is dedicated to advancing innovative therapies in the oncology and autoimmune disease sectors. Founded in 2015, the company has rapidly established itself as a key player in the industry, focusing on the development of novel treatments that address unmet medical needs. With a robust pipeline of targeted therapies and monoclonal antibodies, Innocare Pharma distinguishes itself through its commitment to research and development, leveraging cutting-edge technology to enhance patient outcomes. The company has achieved significant milestones, including successful clinical trials and strategic partnerships, solidifying its position in the global market. As Innocare Pharma continues to expand its operational reach, it remains focused on delivering high-quality, effective solutions that improve the lives of patients worldwide.
DitchCarbon Score
How does Innocare Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Innocare Pharma's score of 4 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Innocare Pharma's reported carbon emissions
Innocare Pharma, headquartered in China, has reported its carbon emissions data for the years 2020 to 2023. In 2023, the company emitted approximately 12,114,590 kg CO2e in Scope 2 emissions, alongside 19,950 kg CO2e in Scope 1 emissions, totalling about 12,134,540 kg CO2e. This marks a significant increase from 2022, where total emissions were approximately 9,835,800 kg CO2e, all from Scope 2. In 2021, Innocare Pharma's emissions reached about 9,236,400 kg CO2e, again solely from Scope 2, while in 2020, the total emissions were approximately 2,476,590 kg CO2e, entirely from Scope 2 as well. The company has not disclosed any specific reduction targets or initiatives, indicating a lack of formal climate pledges or commitments at this time. Overall, Innocare Pharma's emissions profile highlights a growing trend in carbon output, particularly in Scope 2 emissions, which are primarily associated with purchased electricity. The absence of reduction targets suggests that the company may need to enhance its climate strategy to align with industry standards and expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | 00,000 |
| Scope 2 | 2,476,590 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Innocare Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
